Sanofi : Opella deal: a slightly better-than-expected valuation
>Partial divestment of its Consumer business and 2024 guidance revised up - As expected, Sanofi has announced its decision to sell part (50%) of its OTC business to the CD&R fund, but will retain a significant stake in the franchise (48% / Bpifrance has a 2% stake in the entity). The total valuation of this business is € 16bn (i.e. around 14x EBITDA 2024), which is slightly higher than the figure that had been circulating in the market hitherto (€ 15bn). The deal...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.